STEM CELLS UNLOCKED
Syntax Bio is a preclinical-stage biotech company overcoming the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
TECHNOLOGY
Our Cellgorithm technology provides control over the complex developmental biology needed to manufacture stem cell-derived cell therapies.
The Syntax platform provides customizable, epigenetic instructions to program step-wise cellular differentiation processes
INVESTORS
TEAM
LEADERSHIP TEAM
Brad Merrill, PhD
Cofounder, Head of Innovation
Niko Balanis, PhD
Cofounder, VP Data Sci & Molecular Bio
Nick Timmins, PhD
CSO
Ryan Clarke, PhD
Cofounder, CTO
John Flavin, MBA
CEO
BOARD OF DIRECTORS
John Flavin, MBA
Ryan Clarke, PhD
Andy May, DPhil
Executive Chairman; Entrepreneur in Residence, DCVC Bio
Satoshi Konagai, MS, MBA
Investment Lead, Astellas Venture Management
ADVISORS
Matt MacDougall, MD, PhD
Scientific Cofounder, Immunology Physician, Stanford University
Alex Chavez, MD, PhD
Associate Professor, UCSD
Ryan Larson, PhD
Head of Translation, Umoja Biopharma
Ryan Crisman, PhD
Cofounder, CTO Umoja Biopharma
PRESS
September 18, 2024
CRAIN’S CHICAGO BUSINESS: Stem cell tech startup with UIC roots raises $15 million
September 17, 2024
September 17, 2024
September 24, 2023
JANUARY 21, 2021
CONTACT